This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Patel, M. B. Articles by LeJemtel, T. H. Search for Related Content PubMed PubMed Citation Articles by Patel, M. B. Articles by LeJemtel, T. H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Failure Related Collections Contractile function Other heart failure Cardiovascular Pharmacology

(Circulation. 1999;99:60-64.)
© 1999 American Heart Association, Inc.

Clinical Investigation and Reports

Sustained Improvement in Flow-Mediated Vasodilation After Short-Term Administration of Dobutamine in Patients With Severe Congestive Heart Failure

Mrugesh B. Patel, MD; Ilya V. Kaplan, MD; Rajiv N. Patni, MD; Daniel Levy, MD; Joel A. Strom, MD; Jamshid Shirani, MD; Thierry H. LeJemtel, MD

From the Department of Medicine, Division of Cardiology, The Albert Einstein College of Medicine, Bronx, NY.

Correspondence to Thierry H. Lejemtel, MD, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461.

Background—In patients with severe congestive heart failure (CHF), short-term administration of dobutamine exerts sustained clinical benefits that are partially mediated by a training-like effect on skeletal muscle. Recently, physical training has been shown to enhance endothelial function in the skeletal muscle vasculature by improving endothelial function. Whether the dobutamine-induced training effect is also associated with an improvement in endothelial function in the skeletal muscle vasculature is currently unknown.

Methods and Results—Flow-mediated vasodilation in response to peak reactive hyperemia was evaluated in the forearms of 9 patients with severe CHF who were treated with dobutamine for 72 hours. Resting and peak hyperemic brachial artery blood flow and diameter (BABF [mL/min] and BAD [mm], respectively) were measured by 2-dimensional and Doppler ultrasonography at baseline, at 3 and 72 hours during dobutamine infusion, and at 2 and 4 weeks after discontinuation of dobutamine therapy. In addition, the brachial artery response to sublingual (SL) administration of nitroglycerin (NTG) was evaluated at baseline and at 2 and 4 weeks after discontinuation of dobutamine therapy. Ten patients with severe CHF who did not receive dobutamine served as control subjects. Resting BABF was significantly increased at 3 and 72 hours (391.2±31.8 and 366.8±31.0 mL/min, respectively, compared with 289.8±18.6 mL/min at baseline; P<0.05). Peak hyperemic BABF was not altered by dobutamine infusion compared with baseline values. The increase in BAD during peak hyperemic response was greater after infusion of dobutamine for 72 hours (15.2±2.7% versus 9.1±1.8%, P<0.05) and remained significantly greater for 2 weeks after discontinuation of dobutamine (12.3±2.2% versus 9.1±1.8%, P<0.05). In contrast to the peak hyperemic response, the increase in BAD (%) induced by SL NTG was unchanged by administration of dobutamine for 72 hours. Two and 4 weeks after discontinuation of dobutamine, NTG-induced increases in BAD were similar to the BAD noted at baseline.

Conclusions—In patients with severe CHF, short-term administration of dobutamine for 72 hours selectively improves vascular endothelial function for 2 weeks.

Key Words: heart failure • nitroglycerin • vasodilation

This article has been cited by other articles:

				E. R. Schwarz, S. Rastogi, V. Kapur, N. Sulemanjee, and J. J. Rodriguez Erectile Dysfunction in Heart Failure Patients J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1111 - 1119. [Abstract] [Full Text] [PDF]

				P. C. Colombo, J. E. Banchs, S. Celaj, A. Talreja, J. Lachmann, S. Malla, N. B. DuBois, A. W. Ashton, F. Latif, U. P. Jorde, et al. Endothelial Cell Activation in Patients With Decompensated Heart Failure Circulation, January 4, 2005; 111(1): 58 - 62. [Abstract] [Full Text] [PDF]

				S. Mak and G. E. Newton Redox modulation of the inotropic response to dobutamine is impaired in patients with heart failure Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H789 - H795. [Abstract] [Full Text] [PDF]

				M. Crowther, A. Maroulis, N. Shafer-Winter, and R. Hader Evidence-based development of a hospital based heart failure centre Evid. Based Nurs., January 1, 2003; 6(1): 4 - 6. [Full Text] [PDF]

				T. Kihara, S. Biro, M. Imamura, S. Yoshifuku, K. Takasaki, Y. Ikeda, Y. Otuji, S. Minagoe, Y. Toyama, and C. Tei Repeated sauna treatment improves vascular endothelial and cardiac function in patients with chronic heart failure J. Am. Coll. Cardiol., March 6, 2002; 39(5): 754 - 759. [Abstract] [Full Text] [PDF]